PL3801515T3 - 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion i jego sole do zastosowania w leczeniu chorób mitochondrialnych - Google Patents

5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion i jego sole do zastosowania w leczeniu chorób mitochondrialnych

Info

Publication number
PL3801515T3
PL3801515T3 PL19742480.7T PL19742480T PL3801515T3 PL 3801515 T3 PL3801515 T3 PL 3801515T3 PL 19742480 T PL19742480 T PL 19742480T PL 3801515 T3 PL3801515 T3 PL 3801515T3
Authority
PL
Poland
Prior art keywords
thiazolidine
dione
pyridin
ethoxy
hydroxyethyl
Prior art date
Application number
PL19742480.7T
Other languages
English (en)
Inventor
Marc Martinell Pedemonte
Maria Pilar Pizcueta Lalanza
Laura Pilar RODRÍGUEZ PASCAU
Original Assignee
Minoryx Therapeutics S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S.L. filed Critical Minoryx Therapeutics S.L.
Publication of PL3801515T3 publication Critical patent/PL3801515T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19742480.7T 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion i jego sole do zastosowania w leczeniu chorób mitochondrialnych PL3801515T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382397 2018-06-06
PCT/IB2019/054696 WO2019234664A1 (en) 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases

Publications (1)

Publication Number Publication Date
PL3801515T3 true PL3801515T3 (pl) 2025-07-14

Family

ID=62716008

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19742480.7T PL3801515T3 (pl) 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion i jego sole do zastosowania w leczeniu chorób mitochondrialnych

Country Status (13)

Country Link
US (2) US11957670B2 (pl)
EP (2) EP3801515B1 (pl)
JP (1) JP7376934B2 (pl)
DK (1) DK3801515T3 (pl)
ES (1) ES3028538T3 (pl)
FI (1) FI3801515T3 (pl)
HR (1) HRP20250591T1 (pl)
HU (1) HUE071482T2 (pl)
LT (1) LT3801515T (pl)
PL (1) PL3801515T3 (pl)
PT (1) PT3801515T (pl)
SI (1) SI3801515T1 (pl)
WO (1) WO2019234664A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
JP7734917B2 (ja) 2019-01-28 2025-09-08 ミトコンドリア エモーション， インク． トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
JP7473565B2 (ja) 2019-01-28 2024-04-23 ミトコンドリア エモーション， インク． マイトフュージン活性化物質及びその使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201391017A1 (ru) 2011-01-10 2014-04-30 Зинфандел Фармасьютикалз, Инк. Способы и готовые лекарственные формы для лечения болезни альцгеймера
WO2014210389A1 (en) 2013-06-26 2014-12-31 Rett Syndrome Research Trust Rett syndrome and treatments therefore
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
SG11201608218QA (en) 2014-04-02 2016-10-28 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
US20180364595A1 (en) 2015-09-30 2018-12-20 Nikon Corporation Exposure apparatus, flat panel display manufacturing method, and device manufacturing method
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
CN106202285A (zh) 2016-06-30 2016-12-07 北京百度网讯科技有限公司 搜索结果展示方法和装置
AU2017370003B2 (en) 2016-12-01 2023-04-13 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease
ES2926580T3 (es) 2016-12-23 2022-10-27 Minoryx Therapeutics S L Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma
CN112823004A (zh) 2018-06-06 2021-05-18 米尼奥尔克斯治疗有限公司 5-[[4-[2-[5-乙酰基吡啶-2-基]乙氧基]苄基]-1,3-噻唑烷-2,4-二酮及其盐的用途
CA3102407A1 (en) 2018-06-06 2019-12-12 Minoryx Therapeutics S.L. Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Also Published As

Publication number Publication date
JP7376934B2 (ja) 2023-11-09
EP3801515B1 (en) 2025-04-09
ES3028538T3 (en) 2025-06-19
US20250064791A1 (en) 2025-02-27
EP3801515A1 (en) 2021-04-14
HRP20250591T1 (hr) 2025-07-04
FI3801515T3 (fi) 2025-05-27
PT3801515T (pt) 2025-06-11
SI3801515T1 (sl) 2025-07-31
US20210228559A1 (en) 2021-07-29
HUE071482T2 (hu) 2025-08-28
WO2019234664A1 (en) 2019-12-12
EP4545142A2 (en) 2025-04-30
LT3801515T (lt) 2025-06-10
DK3801515T3 (da) 2025-04-28
EP4545142A3 (en) 2025-06-11
US11957670B2 (en) 2024-04-16
JP2021527049A (ja) 2021-10-11

Similar Documents

Publication Publication Date Title
IL279186A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts
IL279183A (en) Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione
HUE059604T2 (hu) Eljárás 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindion és sói elõállítására
PT3801515T (pt) 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona e seus sais para uso no tratamento de doenças mitocondriais
JP2014528450A5 (pl)
HUE054346T2 (hu) 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére
IL288508A (en) History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human ctps1 inhibitors to treat proliferative diseases
JP2014528486A5 (pl)
EA202091120A2 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
CL2010001636A1 (es) (r,z)-5-(2-(3-aminopiperidin-1-il)-3-isopropoxibencilideno)tiazolidin-2,4-diona, (r,z)-5-(2-(3-aminopiperidin-1-il)bifenil-3-ilmetilen)tiazolidin-2,4-diona, o una sal de los mismos; composicion farmaceutica; uso para el tratamiento del cancer y para la inhibicion de quinasa pim.
FI3511319T3 (fi) Lysiinispesifisen demetylaasi-1:n inhibiittoreita
PE20190805A1 (es) Compuesto de piridina
WO2009015812A3 (de) Prodrugs des 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrils
CL2014000149A1 (es) Metodo para sintetizar n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil) fenil)]acetamida y mesilato monohidrato cristalino del mismo; composicion farmaceutica que lo contiene; combinacion farmaceutica; uso en el tratamiento y/o profilaxis de una infeccion por virus herpes simplex.
LT3515910T (lt) 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-izoindol-1-ono dariniai ir jų naudojimas kaip fosfatatidilitinozitol 3-kinazės delta ir gama dvejopų inhibitorių
BR112022021951A2 (pt) Leriglitazona para o tratamento de inflamação pulmonar e doença pulmonar intersticial
RU2015126293A (ru) Производные тиазола в качестве ингибиторов тирозинкиназы брутона
HK40050840A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
HK40049678A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
PT3980411T (pt) N-(5-(6-etoxipirazin-2-il)piridin-2-il)-4-(2-(etilsulfonamido)pirimidin-4-il)tetra-hidro-2h-piran-4-carboxamida como um inibidor de ctps1 humana para o tratamento de doenças proliferativas
AU2018900114A0 (en) 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents